Flow Cytometry is readily amenable to intracellular target detection and can be successfully applied to the study of complex signaling pathways
Multiplex IHC - Being able to visualize multiple targets simultaneously is important in research fields like immunology & oncology. Learn more here.
The Lambda Protein Phosphatase #56206 included in the Lambda Protein Phosphatase Kit #89726 is temperature sensitive. Therefore, we recommend storing the kit at -80°C.
Necrosis has been classically defined as an unprogrammed form of cell death that occurs in response to overwhelming chemical or physical insult.
A Hallmark of Cancer, sustaining proliferative signaling is used by cancer cells to stimulate growth and relies on Akt, MAPK/Erk, and MTOR pathways.
Lymphoid lineage cells can be characterized using antibodies for cell type-specific markers, allowing cells to be visualized using flow cytometry or IHC.
The TGF-β Antibody #3711 detects recombinant TGF-β1, TGF-β2, and TGF-β3. The antibody also detects endogenous levels of the TGF-β1 precursor proteins.
A scientific resource for the 14-3-3 protein domain containing information on structure, function, and binding to phospho-serine and phospho-threonine motifs.
U.S. Patent No. 6,441,140, directed to the production of a novel class of motif-specific, context-independent antibodies, highly useful for the identification of subclasses of protein kinase substrates.
Feb 2008, CST continued collaboration with AstraZeneca to provide CST’s PhosphoScan® Platform for kinase inhibitor proteomic profiling.
Cell Signaling Technology, a leading provider of antibodies, kits and services, announced today that it has won two Life Science Industry Awards® for "Best Antibodies" and "Most Useful Website."
Announce partnership with this local 1% for the Planet startup to help share and promote best practices for sustainability. Also, to encourage other companies to do the same by promoting recent sponsorship of NSTC as part of our ESR activities.
MEDx and CST announce expansion of their ongoing partnership for companion diagnostic (CDx) development using CST® antibodies to meet growing demand in China.
CST and The Michael J. Fox Foundation (MJFF) announce a partnership to develop high-quality monoclonal antibodies against promising Parkinson’s disease (PD) targets.
Antibody selection and optimization for immunoprecipitation in your ChIP protocol. How specificity, signal-to-noise ratio and concentration impact results.
PTMScan videos and links to complementary technologies for phospho-peptide enrichment and Science Webinar on Proteomics and Cell Signaling.
CST and Amoy Diagnostics announced the expansion of their collaboration to use CST antibodies in companion diagnostics to aid growing oncology needs in China.
CST believes in a data driven approach to continuous improvement and implementation of business practices that minimize negative impact on nature.}{icon: sustainability
Will an antibody validated for WB perform as expected in an IF experiment? Here, we compare an IF-validated mAb from CST to one from another vendor.
